We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Onyx’s Drug Gets Standard Review, Accelerated Approval in Question
Onyx’s Drug Gets Standard Review, Accelerated Approval in Question
December 16, 2011
Onyx Pharmaceuticals’ multiple myeloma drug carfilzomib will receive a standard, 10-month, FDA review, another hurdle for the compound, which was expected to receive priority review.